bioMérieux: FDA 510(k) clearances across all its applicant names
FDA lists 416 510(k) clearances, 4 PMA and 7 De Novo decisions across the 10 applicant names Caduvo groups under bioMérieux, first 1978, latest 2026. Median 510(k) review time across these names: 82 days. Since 2017 the median was 90 days, against 94 days for all cleared 510(k)s in the same product codes. Groups are curated by Caduvo from public sources listed below; FDA does not group applicants. Counts include filings made before an acquisition, and can include older filings by a business that was later sold when FDA records them under the same applicant name; see the notes on this page.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2012 | 12 | 206 |
| 2013 | 14 | 98 |
| 2014 | 4 | 152 |
| 2015 | 7 | 113 |
| 2016 | 12 | 89 |
| 2017 | 18 | 90 |
| 2018 | 8 | 122 |
| 2019 | 14 | 80 |
| 2020 | 7 | 81 |
| 2021 | 8 | 222 |
| 2022 | 12 | 189 |
| 2023 | 13 | 98 |
| 2024 | 10 | 87 |
| 2025 | 7 | 90 |
| 2026 | 13 | 89 |
The 10 FDA applicant names in this group
| Applicant name | 510(k) clearances | PMA | De Novo | Years |
|---|---|---|---|---|
| bioMerieux, Inc. | 261 | 3 | 1 | 1983–2026 |
| Biomerieux Vitek, Inc. | 49 | 1 | 0 | 1992–1998 |
| Vitek Systems, Inc. | 39 | 0 | 0 | 1978–1993 |
| Biofire Diagnostics, LLC | 26 | 0 | 4 | 2015–2026 |
| Biomerieux S.A. | 16 | 0 | 0 | 2011–2025 |
| Biofire Defense, LLC | 9 | 0 | 2 | 2017–2026 |
| Biofire Diagnostics, Inc. | 8 | 0 | 0 | 2013–2026 |
| Biomérieux SA | 4 | 0 | 0 | 2020–2026 |
| Ab Biomerieux | 2 | 0 | 0 | 2009–2010 |
| Biofire Diagnostics, LLC (Biomerieux) | 2 | 0 | 0 | 2024–2024 |
Review time against the same product codes
Since 2017, 510(k)s cleared under these names took a median 90 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 94 days.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| LON | System, Test, Automated, Antimicrobial Susceptibility, Short Incubation | 120 | 120 |
| JWY | Manual Antimicrobial Susceptibility Test Systems | 19 | 19 |
| JSJ | Culture Media, Selective And Non-Differential | 18 | 18 |
| JSG | Culture Media, Non-Selective And Non-Differential | 13 | 13 |
| JSH | Culture Media, Non-Selective And Differential | 12 | 12 |
| MDB | System, Blood Culturing | 12 | 12 |
| JSI | Culture Media, Selective And Differential | 11 | 11 |
| NGZ | Susceptibility Test Plate, Antifungal | 11 | 11 |
| JSF | Culture Media, Single Biochemical Test | 7 | 7 |
| PCH | Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System | 7 | 7 |
Plus 116 more product codes.
Review panels
- Microbiology (353)
- Clinical Chemistry (27)
- Hematology (23)
- Immunology (11)
- Clinical Toxicology (8)
- Pathology (1)
- General and Plastic Surgery (1)
Most recent bioMérieux 510(k) clearances
| 510(k) | Device | Applicant name | Product code | Decision date | Review days |
|---|---|---|---|---|---|
| K262172 | BIOFIRE FILMARRAY Gastrointestinal 1.1 (GI1.1) Panel; BIOFIRE FILMARRAY Gastrointestinal 1.1 (GI1.1) Panel Mid | Biofire Diagnostics, LLC | PCH | 2026-11-06 | 133 |
| K262842 | BioFire Warrior Panel Control Kit | Biofire Defense, LLC | PMN | 2026-11-04 | 84 |
| K262807 | VITEK 2 AST-Gram Negative Polymyxin B (<= 0.25 >=16µg/mL);VITEK 2 AST-Gram Negative Imipenem (<= 0.25 >=16µg/mL);VITEK 2 AST-Gram Negative Ceftazidime Avibactam (<= 0.125 >=16µg/mL) | bioMerieux, Inc. | LON | 2026-11-04 | 89 |
| K262683 | VITEK PRO | bioMerieux, Inc. | LON | 2026-11-03 | 95 |
| K262136 | BIOFIRE SPOTFIRE Vaginitis (VG) Panel | Biofire Diagnostics, LLC | PQA | 2026-10-21 | 118 |
| K260283 | VITEK 2 AST-Streptococcus Meropenem (=0.06 - =4 µg/mL) | bioMerieux, Inc. | LON | 2026-10-01 | 245 |
| K260619 | VITEK 2 AST-Streptococcus Cefepime (<=0.06 >=4 µg/mL) | bioMerieux, Inc. | LON | 2026-09-28 | 215 |
| K263054 | BIOFIRE Respiratory Panel 2.1 (RP2.1) | Biofire Diagnostics, Inc. | QOF | 2026-09-22 | 21 |
| K261475 | BIOFIRE® FILMARRAY® Tropical Fever Panel Control Kit | Biofire Defense, LLC | PMN | 2026-07-17 | 73 |
| K260160 | VITEK REVEAL GN AST Assay and VITEK REVEAL AST System | bioMerieux, Inc. | SAN | 2026-07-08 | 169 |
406 earlier clearances. See the full list in Caduvo.
PMA and De Novo decisions
| Number | Pathway | Device | Decision date |
|---|---|---|---|
| DEN200066 | De Novo | Orthopedic Infection Microbial Multiplex Nucleic Acid Detection System | 2022-04-29 |
| DEN200031 | De Novo | Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents | 2021-03-17 |
| DEN200043 | De Novo | Device To Detect And Identify Selected Microbial Agents That Cause Acute Febrile Illness | 2020-11-20 |
| DEN170017 | De Novo | Mers-Cov And Common Respiratory Pathogens Multiplex Nucleic Acid Detection System | 2017-11-24 |
| DEN160048 | De Novo | 2017-02-14 |
Recalls
682 product recalls in 152 recall events under these names; 137 initiated in the last five years.
5 product recalls in 5 recall events filed under other recalling-firm names cite a 510(k) or PMA held under these applicant names; 2 initiated in the last five years. Most often: Biofire Defense (4), Biomerieux France Chemin De L'Or (1).
These recall records list the clearance number, so the device was cleared under this name. The recalling firm may be the same company under another spelling, a company that acquired the product line, a relabeler or a contract manufacturer. They are not added to the count above.
Recalling firms are matched to the applicant names above by name only, so recalls filed under other names are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Device clinical trials
ClinicalTrials.gov lists 6 device studies (0 active or recruiting) with an industry lead sponsor under the 3 sponsor names below. Most recent:
- NCT07513519: Impact of a Multiplex Respiratory PCR Test on Outcomes for Patients Presenting With Respiratory Illness in the Urgent Care Setting: A Hybrid-Effectiveness Quasi-Experimental Trial (BioMérieux; Completed, started 2025-12-22)
- NCT07221097: Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses (BioFire Defense LLC; Completed, started 2025-09-29)
- NCT06037109: VIDAS® NEPHROCLEAR Reference Interval Study (BioMérieux; Completed, started 2023-07-18)
- NCT04434209: A Study Looking at the Use of Biomarkers to Provide Early Indication of Acute Kidney Injury in Patients With Sepsis (Limiting AKI Progression In Sepsis) (BioMérieux; Terminated, started 2021-01-19)
- NCT03029299: Implementation Assessment and Clinical Utility of the FilmArray® Respiratory Panel (RP) EZ in a CLIA-waived Setting (BioFire Diagnostics, LLC; Completed, started 2017-04-04)
| Lead sponsor name on ClinicalTrials.gov | Device studies |
|---|---|
| BioMérieux | 3 |
| BioFire Diagnostics, LLC | 2 |
| BioFire Defense LLC | 1 |
Sponsor names are matched to the applicant names above by name, with punctuation and legal suffixes removed, plus sponsor names reviewed for this group. Studies listed under other sponsor names are not counted.
How this group is built
Groups are curated by Caduvo from public sources listed below; FDA does not group applicants. Counts include filings made before an acquisition, and can include older filings by a business that was later sold when FDA records them under the same applicant name; see the notes on this page.
Vitek Systems (1988), Organon Teknika's diagnostics business (2001; the ORGANON TEKNIKA names are left out because that company also had other lines), BioFire (2014). Includes filings made before each acquisition. Left out: ORGANON (plain), which is a different, pharma-related applicant.
Sources
Frequently asked questions
How many FDA 510(k) clearances are listed across bioMérieux's applicant names?
FDA lists 416 510(k) clearances, 4 PMA and 7 De Novo decisions across the 10 applicant names Caduvo groups under bioMérieux, first 1978, latest 2026. FDA records each applicant name separately; Caduvo adds up the names listed on this page.
Which FDA applicant names does bioMérieux file under?
The names with the most 510(k) clearances in this group are bioMerieux, Inc. (261); Biomerieux Vitek, Inc. (49); Vitek Systems, Inc. (39); Biofire Diagnostics, LLC (26); Biomerieux S.A. (16). The full list of 10 names is on this page.
How long does FDA take to clear bioMérieux 510(k)s?
The median time from FDA receipt to decision across 510(k)s cleared under these names is 82 days. Since 2017 the median was 90 days, against 94 days for all cleared 510(k)s in the same product codes.
Does the bioMérieux count include acquired companies?
Yes. A group includes filings an acquired business made under its own name, including before the acquisition. Businesses that were sold are left out, and names whose ownership is unclear are not included. FDA does not group applicants; the sources for each grouping are listed on this page.
How many device clinical trials does bioMérieux sponsor?
ClinicalTrials.gov lists 6 device studies (0 active or recruiting) with an industry lead sponsor under 3 sponsor names Caduvo groups under bioMérieux. ClinicalTrials.gov names the sponsor on each study; Caduvo adds up the names listed on this page.
Next steps
- See all 416 bioMérieux clearances with predicates and recalls
- Run predicate analysis for product code LON, bioMérieux's most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this grouping or data. Data and corrections policy.
All parent companies · FDA device companies by applicant name · FDA product code lookup